VCAM-1-TARGETED nanoparticles
VCAM-1-TARGETED nanoparticles has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Jul 8, 2026: “VCAM-1-targeting peptide assemblies protect vascular endothelium and prolong cardiac xenograft survival”.
1 paper studies it2 findingsUpdated
- 1 lab in 1 country
- Funders: National High Level Hospital Clinical Research Funding and 2 more
- Animals1
What did studies of VCAM-1-TARGETED nanoparticles find?
2Studies of VCAM-1-TARGETED nanoparticles measured 2 outcomes; the most studied are graft survival (1 study) and immune cell adhesion (1).
Graft survival
upin non-human primates1
1 study
Graft survival
upin non-human primates1
VCAM-1-TARGETED nanoparticles improve graft survival in non-human primates (from 6.7 to 27.0 days (nearly fourfold)).
“extends xenograft survival nearly fourfold, from 6.7 to 27.0 days.”
Animalsporcine-to-primate cardiac xenotransplantation
Science advances
Immune cell adhesion
downin non-human primates1
1 study
Immune cell adhesion
downin non-human primates1
VCAM-1-TARGETED nanoparticles decrease immune cell adhesion in non-human primates (-73% (P < 0.001)).
“VTN reduces immune cell adhesion by 73% (P < 0.001)”
Animalscardiac xenograft
Science advances